No Prescription |
 |
 | ||
|
Tripress Surmontil |
|
| ||
No Prescription » Prescription Drugs 16 » Tripress Surmontil TRIPRESS is indicated in the treatment of depressive illness especially where sleep disturbance anxiety or agitation is a presenting symptom. Sleep disturbance is controlled within 24 hours and true antidepressant action follows within 7-10 days.Dosage and AdministrationAdultsMild/Moderate Depression in General PracticeThe recommended dosage is 50-75mg orally given two hours before bedtime the larger dose (75mg) being preferable for those patients with more marked sleep disturbance. Treatment should be continued for at least three weeks.Moderate/Severe Depression (Patients under Psychiatric Supervision)Initial dosage - 75mg orally per day. This is best given as a single dose late in the evening or as 25mg midday and 50mg late in the evening. Dosage should then be increased as necessary until the optimal therapeutic level is reached usually 150-300mg per day. Treatment at this dosage should be continued for four to six weeks dosage then being reduced to a maintenance level usually within the range of 75-150mg per day for two to three months. Giving most of the total daily dosage at night induces a rapid return to normal sleep reduces the need for night-time sedation and minimises daytime drowsiness.ElderlyInitially 10-25mg three times a day. The initial dose should be increased with caution under close supervision.Half the normal maintenance dose may be sufficient to produce a satisfactory clinical response.Adolescent DepressionNot recommended for use in adolescent patients 13-18 years of age for the treatment of depression unless under the supervision of a specialist.Impaired Liver FunctionAs trimipramine is metabolised in the liver patients with liver disease may require a reduced dosage.Renal FailureTrimipramine should be used with caution in patients with chronic renal failure.Cyclothymic patients with recurrent depression may require maintenance therapy for up to one year or even longer.When discontinuing treatment with TRIPRESS this should be done with a gradually reducing dosage regimen. If during this regimen there are signs of a relapse patients should be maintained on the therapy for a further 3-6 months before a second attempt at treatment discontinuation is made. Buy Tripress Surmontil and other Prescription Drugs 16 products online at Medstore. Buy Online at Medstore - Click Here!
About Tripress Surmontil: Product Type: Prescription Drugs 16 Tripress ( Surmontil Generic Trimipramine ) Tripress (Surmontil Generic Trimipramine) Surmontil Generic Trimipramine 25mg 100 Tablets 25mg 200(2 x 100) Tablets 25mg 400(4 x 100) Tablets 50mg 100 Tablets 50mg 200(2 x 100) Tablets 50mg 400(4 x 100) Tablets Surmontil Generic Trimipramine Tripress
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
